Catalyst
Slingshot members are tracking this event:
PharmaMar (PHM.MC) Expects Recruitment to Conclude in 2018 for Phase 3 Registration Trial Evaluating Lurbinectedin (PM1183) in Small-Cell Lung Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PHM.MC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 18, 2018
Occurred Source:
https://www.pharmamar.com/wp-content/uploads/2018/01/HR-English-18.01.2018.pdf
Related Projects
- A conversation with PharmaMar's Director of Oncology, Newly Hired COO, and Director of Capital Markets to discuss the upcoming pivotal year for the firm. PHM.MC, CLVS, TSRO Executed On: Mar 09, 2017 at 11:00 AM EST
Related Keywords
Recruitment, Phase 3, Registration Trial, Lurbinectedin, Pm1183, Small-cell Lung Cancer
